Skip to main content

Spruce Street Capital LP

SEC CIK
0002050194
Latest filing
Aug 13, 2026

The latest 13F from Spruce Street Capital LP covers Q2 2026 (filed Aug 13, 2026): 30 long positions worth $509.7M. The top 10 holdings make up 70.2% of the portfolio, and the largest is Kiniksa Pharmaceuticals International, plc (KNSA) at 11.5%. Livermore has 3 filings on Form 13F from this institution, going back to Q4 2025.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
5
Est. +$29.3M
Added
8
Est. +$33.4M
Reduced
1
Est. −$1.80M
Sold out
3
Est. −$43.5M

Top 5 holdings

Share of this quarter's portfolio value

  1. KNSAKiniksa Pharmaceuticals International, plc
    11.5%$58.7MHistory
  2. RLAYRelay Therapeutics, Inc.
    11.0%$55.8MHistory
  3. LBRXLB Pharmaceuticals Inc
    8.8%$44.7MHistory
  4. RLMDRelmada Therapeutics, Inc.
    8.7%$44.2MHistory
  5. ANROAlto Neuroscience, Inc.
    7.0%$35.7MHistory

Share of portfolio

Top 5 holdings and the other 25 positions, by share of portfolio value

  1. KNSA11.5%
  2. RLAY11.0%
  3. LBRX8.8%
  4. RLMD8.7%
  5. ANRO7.0%
  6. Other 25 positions53.1%

Biggest buys

New and added positions, by estimated amount bought

  1. IFRXInflaRx N.V.
    +$12.0MNewHistory
  2. ALKSAlkermes plc.
    +$11.8MAddedHistory
  3. KNSAKiniksa Pharmaceuticals International, plc
    +$10.0MAddedHistory
  4. RACCResearch Alliance Corp III
    +$5.35MNewHistory
  5. ZLABZai Lab Ltd
    +$5.30MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ALKSAlkermes plc.
    +2.89 pp2.7% → 5.6%History
  2. KNSAKiniksa Pharmaceuticals International, plc
    +2.71 pp8.8% → 11.5%History
  3. IFRXInflaRx N.V.
    +2.35 pp0.0% → 2.4%History
  4. RACCResearch Alliance Corp III
    +1.05 pp0.0% → 1.0%History
  5. ZLABZai Lab Ltd
    +1.04 pp0.0% → 1.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CNTACentessa Pharmaceuticals plc
    −$19.5MSold outHistory
  2. KALVKalVista Pharmaceuticals, Inc.
    −$18.1MSold outHistory
  3. MAZEMaze Therapeutics, Inc.
    −$5.97MSold outHistory
  4. DNTHDianthus Therapeutics, Inc.
    −$1.80MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CNTACentessa Pharmaceuticals plc
    −4.68 pp4.7% → 0.0%History
  2. KALVKalVista Pharmaceuticals, Inc.
    −4.34 pp4.3% → 0.0%History
  3. MAZEMaze Therapeutics, Inc.
    −1.44 pp1.4% → 0.0%History
  4. DNTHDianthus Therapeutics, Inc.
    −0.75 pp7.5% → 6.8%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$509.7M
+$93.7M (+22.5%) vs. prior quarter
Positions
30
+2 vs. prior quarter
Top 10 concentration
70.2%
Top 10 as share of value
Turnover
9.8%
Q2 2026, one quarter
Average holding period
2.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2025), so positions held before then are understated.

13F filings by quarter

3 quarters, going back to Q4 2025. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $509.7M (Q2 2026)

Q4 2025: $302.7MQ1 2026: $415.9MQ2 2026: $509.7M
Q4 2025Q2 2026
13F filings of Spruce Street Capital LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 13, 202630$509.7MKNSARLAYLBRXvs. Q1 2026SEC
Q1 2026May 14, 202628$415.9MRLMDKNSALBRXvs. Q4 2025SEC
Q4 2025Feb 13, 202627$302.7MCDTXRLAYLBRX–SEC

13D and 13G filings

Companies where Spruce Street Capital LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

2 companies, largest stake first.

Companies where Spruce Street Capital LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
RACCResearch Alliance Corp III13G6.40%500.0K sharesNewAug 13, 20261 filingAug 13, 2026SEC
RLMDRelmada Therapeutics, Inc.13G5.57%4.09M sharesNewFeb 17, 20261 filingFeb 17, 2026SEC

Latest filings

2 filings on file made by Spruce Street Capital LP or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Spruce Street Capital LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
RACCResearch Alliance Corp IIIAug 13, 20268:30 AM ET13G6.40%500.0K sharesNewJun 30, 2026SEC
RLMDRelmada Therapeutics, Inc.Feb 17, 20269:15 AM ET13G5.57%4.09M sharesNewDec 31, 2025SEC